Skip to search formSkip to main contentSkip to account menu

CCX282-B

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Sulfonamides

Narrower (1)

vercirnon

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The role of CCL25 and CCR9 in intestinal inflammation
Leukocyte extravasation is mediated in part by tissue specific chemotactic cytokines (chemokines) and specific chemokine… 
2009
2009
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohnʼs Disease: P-0022.
Review
2008
Review
2008
Chest-Tube Insertion
n engl j med 358;7 www.nejm.org february 14, 2008 749 pathogenesis of celiac disease. In our review, we describe how… 
2007
2007
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)